277 related articles for article (PubMed ID: 33012551)
1. Development of a longitudinal two-biomarker algorithm for early detection of ovarian cancer in women with BRCA mutations.
Lentz SE; Powell CB; Haque R; Armstrong MA; Anderson M; Liu Y; Jiang W; Chillemi G; Shaw S; Alvarado MM; Kushi LH; Skates SJ
Gynecol Oncol; 2020 Dec; 159(3):804-810. PubMed ID: 33012551
[TBL] [Abstract][Full Text] [Related]
2. Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
Haque R; Skates SJ; Armstrong MA; Lentz SE; Anderson M; Jiang W; Alvarado MM; Chillemi G; Shaw SF; Kushi LH; Powell CB
Gynecol Oncol; 2020 May; 157(2):521-528. PubMed ID: 32145911
[TBL] [Abstract][Full Text] [Related]
3. Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.
Karlan BY; Thorpe J; Watabayashi K; Drescher CW; Palomares M; Daly MB; Paley P; Hillard P; Andersen MR; Anderson G; Drapkin R; Urban N
Cancer Epidemiol Biomarkers Prev; 2014 Jul; 23(7):1383-93. PubMed ID: 24789859
[TBL] [Abstract][Full Text] [Related]
4. Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials.
Skates SJ; Greene MH; Buys SS; Mai PL; Brown P; Piedmonte M; Rodriguez G; Schorge JO; Sherman M; Daly MB; Rutherford T; Brewster WR; O'Malley DM; Partridge E; Boggess J; Drescher CW; Isaacs C; Berchuck A; Domchek S; Davidson SA; Edwards R; Elg SA; Wakeley K; Phillips KA; Armstrong D; Horowitz I; Fabian CJ; Walker J; Sluss PM; Welch W; Minasian L; Horick NK; Kasten CH; Nayfield S; Alberts D; Finkelstein DM; Lu KH
Clin Cancer Res; 2017 Jul; 23(14):3628-3637. PubMed ID: 28143870
[No Abstract] [Full Text] [Related]
5. Diagnostic accuracy of CA125 and HE4 in ovarian carcinoma patients and the effect of confounders on their serum levels.
Ahmed AA; Abdou AM
Curr Probl Cancer; 2019 Oct; 43(5):450-460. PubMed ID: 30670303
[TBL] [Abstract][Full Text] [Related]
6. Elevated Serum Level of CA125 Is a Biomarker That Can Be Used to Alter Prognosis Determined by BRCA Mutation and Family History in Ovarian Cancer.
Liu W; Wang Z; Ma J; Hou Y; Zhao J; Dong B; Tu S; Wang L; Guo Y
Genet Test Mol Biomarkers; 2017 Sep; 21(9):547-554. PubMed ID: 28799806
[TBL] [Abstract][Full Text] [Related]
7. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
8. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum CA125, HE4 and CA724 and the risk of ovarian malignancy algorithm score in the diagnosis of high-grade serous ovarian cancer.
Hu D; Qian J; Yin F; Wei B; Wang J; Zhang H; Yang H
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():170-175. PubMed ID: 38663180
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
Skates SJ
Int J Gynecol Cancer; 2012 May; 22 Suppl 1(Suppl 1):S24-6. PubMed ID: 22543916
[TBL] [Abstract][Full Text] [Related]
11. Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population.
Blyuss O; Burnell M; Ryan A; Gentry-Maharaj A; Mariño IP; Kalsi J; Manchanda R; Timms JF; Parmar M; Skates SJ; Jacobs I; Zaikin A; Menon U
Clin Cancer Res; 2018 Oct; 24(19):4726-4733. PubMed ID: 30084833
[No Abstract] [Full Text] [Related]
12. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value.
Lu KH; Skates S; Hernandez MA; Bedi D; Bevers T; Leeds L; Moore R; Granai C; Harris S; Newland W; Adeyinka O; Geffen J; Deavers MT; Sun CC; Horick N; Fritsche H; Bast RC
Cancer; 2013 Oct; 119(19):3454-61. PubMed ID: 23983047
[TBL] [Abstract][Full Text] [Related]
13. Performance of preoperative plasma tumor markers HE4 and CA125 in predicting ovarian cancer mortality in women with epithelial ovarian cancer.
Furrer D; Grégoire J; Turcotte S; Plante M; Bachvarov D; Trudel D; Têtu B; Douville P; Bairati I
PLoS One; 2019; 14(6):e0218621. PubMed ID: 31220149
[TBL] [Abstract][Full Text] [Related]
14. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
15. A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
Lycke M; Kristjansdottir B; Sundfeldt K
Gynecol Oncol; 2018 Oct; 151(1):159-165. PubMed ID: 30149898
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass.
Karlsen MA; Sandhu N; Høgdall C; Christensen IJ; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Lydolph M; Laursen IA; Høgdall EV
Gynecol Oncol; 2012 Nov; 127(2):379-83. PubMed ID: 22835718
[TBL] [Abstract][Full Text] [Related]
17. HE4 combined with CA125: favorable screening tool for ovarian cancer.
Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
[TBL] [Abstract][Full Text] [Related]
18. Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses.
Pitta Dda R; Sarian LO; Barreta A; Campos EA; Andrade LL; Fachini AM; Campbell LM; Derchain S
BMC Cancer; 2013 Sep; 13():423. PubMed ID: 24044637
[TBL] [Abstract][Full Text] [Related]
19. Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis.
Zhang L; Chen Y; Wang K
Curr Probl Cancer; 2019 Apr; 43(2):135-144. PubMed ID: 30017407
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Schummer M; Drescher C; Forrest R; Gough S; Thorpe J; Hellström I; Hellström KE; Urban N
Gynecol Oncol; 2012 Apr; 125(1):65-9. PubMed ID: 22155417
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
